Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions.
作者： Gonzalo Recondo Jr
关键词:
摘要: During the last 15 years we have witnessed an unprecedented expansion in drugs developed to target human epidermal growth factor receptor-2 (HER-2) positive breast cancer. Trastuzumab, pertuzumab, ado-trastuzumab emtansine and lapatinib are currently food drug administration (FDA)-approved for treatment of cancer patients with HER-2 over-expressed. However, given amount information gathered from uninterrupted clinical research, it is essential periodic updates that succinctly recapitulate what learnt over these help us apply our daily practice. This review will pursue objective. We summarize most relevant updated related state art management all scenarios including adjuvant, neoadjuvant metastatic settings. But also critically appraise literature order highlight some key concepts should not be overlooked. Lastly, this point out promising strategies being tested may soon become available.
sci-hub.se 参考文章(97)
Masataka Sawaki, Yoshinori Ito, Keiichiro Tada, Nobuyuki Mizunuma, Shunji Takahashi, Noboru Horikoshi, Fujio Kasumi, Futoshi Akiyama, Goi Sakamoto, Tsuneo Imai, Akimasa Nakao, Kiyohiko Hatake, Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori. ,vol. 90, pp. 40- 43 ,(2004) , 10.1177/030089160409000110
Timothy S. Lewis, Paul S. Shapiro, Natalie G. Ahn, Signal Transduction through MAP Kinase Cascades Advances in Cancer Research. ,vol. 74, pp. 49- 139 ,(1998) , 10.1016/S0065-230X(08)60765-4
Angelo Di Leo, Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. Cancer management and research. ,vol. 2, pp. 13- 25 ,(2010) , 10.2147/CMAR.S8951
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
Ami Citri, Judith Gan, Yaron Mosesson, Gyorgi Vereb, Janos Szollosi, Yosef Yarden, None, Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Reports. ,vol. 5, pp. 1165- 1170 ,(2004) , 10.1038/SJ.EMBOR.7400300
P N Munster, K T Thurn, S Thomas, P Raha, M Lacevic, A Miller, M Melisko, R Ismail-Khan, H Rugo, M Moasser, S E Minton, A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer British Journal of Cancer. ,vol. 104, pp. 1828- 1835 ,(2011) , 10.1038/BJC.2011.156
Kermit L. Carraway, Lewis C. Cantley, A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling Cell. ,vol. 78, pp. 5- 8 ,(1994) , 10.1016/0092-8674(94)90564-9
Gunter von Minckwitz, Kathrin Schwedler, Marcus Schmidt, Jana Barinoff, Christoph Mundhenke, Tanja Cufer, Eduard Maartense, Felix E. de Jongh, Klaus H. Baumann, Joachim Bischoff, Nadia Harbeck, Hans-Joachim Lück, Nicolai Maass, Christoph Zielinski, Michael Andersson, Robert C. Stein, Valentina Nekljudova, Sibylle Loibl, Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer. ,vol. 47, pp. 2273- 2281 ,(2011) , 10.1016/J.EJCA.2011.06.021
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, Alexey Manikhas, Ana Lluch, Sergey Tjulandin, Milvia Zambetti, Federico Vazquez, Mikhail Byakhow, Mikhail Lichinitser, Miguel Angel Climent, Eva Ciruelos, Belén Ojeda, Mauro Mansutti, Alla Bozhok, Roberta Baronio, Andrea Feyereislova, Claire Barton, Pinuccia Valagussa, Jose Baselga, Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet. ,vol. 375, pp. 377- 384 ,(2010) , 10.1016/S0140-6736(09)61964-4
Harold J. Burstein, Aparna Keshaviah, Ari D. Baron, Ronald D. Hart, Rosemary Lambert-Falls, P. Kelly Marcom, Rebecca Gelman, Eric P. Winer, Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study Cancer. ,vol. 110, pp. 965- 972 ,(2007) , 10.1002/CNCR.22885